Pfizer-BioNTech

Dr Robert Hess: Managing the Covid-19 aftermath

Dr Robert Hess: Managing the Covid-19 aftermath: Detox of the spike-protein. Two full years after the pandemic began, it is now time to consider our next moves. In order to maintain a clear overview, I placed great emphasis on accurate documentation and ongoing information exchange right from the start. This meticulous approach, together with insights…

Read More

Dr Robert Hess: FDA approves booster

Dr Robert Hess: FDA approves booster dose of Pfizer-BioNTech vaccine for the over-65s and for vulnerable categories but not yet for the wider population. The issue of booster vaccination has risen high on the agenda, and every country is taking a different approach to it. Israel, Austria and Russia are already offering booster jabs to…

Read More

Dr Robert Hess: A first step in the right direction

Dr Robert Hess: A first step in the right direction: BioNTech introduces the “individualization” concept into vaccination strategy. Where are we now, almost two years into the pandemic? Nine months after the first vaccines for the prevention of Covid-19 were approved, are there any conclusions that can be reliably drawn? Since December 2020, 2.39 billion…

Read More

Dr Robert Hess: Update on new mutations

Dr Robert Hess: Update on new mutations and what you need to know about COVID-19 variants. As experts in the field of human and molecular genetics and thus also on the topic of mutations, we provide regular updates and forecasts of where the pandemic might be heading. Recently, new discoveries have come into the frame,…

Read More